Eli Lilly and Co. remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology, but the company plans to remain on the sidelines when it comes to two of the hottest areas of drug development.
Bankers are diagnosing another robust year for U.S. healthcare lending as the first two big loans of 2019 include the largest-ever tie-up in the pharmaceutical sector, and more are expected.
GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said.
Sanofi will pay Regeneron about $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body’s own immune system fight cancer.
Selecta Biosciences announced restructuring efforts that include reducing the Watertown, Mass.-based company’s workforce by 36 percent.
Germany-based BioNTech extended a three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.
Celgene Corp. and Bristol-Myers Squibb Co. will have to pay $2.2 billion if either of the drugmakers walks away from their $74 billion merger, according to a regulatory filing.
Locus Biosciences inked a collaboration and license deal with J&J’s Janssen Pharmaceutical to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage.
Bristol-Myers Squibb Co. will buy Celgene Corp. for about $74 billion, creating one of the largest pharmaceutical companies and combining two significant cancer medicine businesses.
Boston Scientific exercised the company’s option to buy the remaining shares of Santa Rosa, Calif.-based Millipede for $325 million.